SCHEMBL4511065

SCHEMBL4511065

CC1(O)CCC(N2CCC(Cc3ccc(NC(=O)Nc4ccc(C(=O)O)cc4)cc3Cl)C2=O)CC1

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EPHX2 P34913 2/20 0.36
F11 P03951 2/20 0.35
KLKB1 P03952 2/20 0.35
CMA1 P23946 1/20 0.35
FPR2 P25090 1/20 0.35
MTHFD2 P13995 1/20 0.35
MEN1 O00255 3/20 0.35
KMT2A Q03164 3/20 0.35
NPC1 O15118 2/20 0.35
RAB9A P51151 2/20 0.35
SMN1; SMN2 Q16637 2/20 0.35
LMNA P02545 1/20 0.35
HTT P42858 1/20 0.35
MAPT P10636 1/20 0.35
CASP3 P42574 1/20 0.35
SENP7 Q9BQF6 1/20 0.35
RARB P10826 1/20 0.35
CBS P35520 1/20 0.34
KCNJ6 P48051 1/20 0.34
KCNJ5 P48544 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4514645 0.89 TRPV1 (0.44) MEN1KMT2ARAB9ASMN1; SMN2LMNA
SCHEMBL5548898 0.87 RORC (0.39) SMN1; SMN2MAPTHSD11B1P2RX7
SCHEMBL4514423 0.87 CHRM1 (0.43) KMT2ANPC1RAB9ALMNAHTT
SCHEMBL4505621 0.86 NPY2R (0.36) MEN1KMT2AMAPTHSD11B1THRB
SCHEMBL4514917 0.86 KMT2A (0.42) EPHX2MEN1KMT2ASMN1; SMN2LMNA
SCHEMBL4505657 0.85 EPHX2 (0.41) EPHX2SMN1; SMN2HSD11B1P2RX7
SCHEMBL4514431 0.84 KMT2A (0.44) MEN1KMT2ANPC1RAB9ASMN1; SMN2
SCHEMBL13674531 0.82 BMPR1B (0.38) MEN1KMT2ANPC1SMN1; SMN2HTT
SCHEMBL4528168 0.82 BMPR1B (0.38) MEN1KMT2ANPC1SMN1; SMN2HTT
SCHEMBL4514751 0.82 PTGDR2 (0.44) MEN1KMT2ANPC1RAB9ASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090264650-A1 Prophylactic/Therapeutic Agent for Diabetes TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-10-22 US disclosed
US-20090264650-A1 Prophylactic/Therapeutic Agent for Diabetes TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-10-22 US disclosed
EP-1864971-A1 PROPHYLACTIC/THERAPEUTIC AGENT FOR DIABETES Takeda Pharmaceutical Company Limited (JP) 2007-12-12 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090264650-A1 Prophylactic/Therapeutic Agent for Diabetes HSD11B1, HSD17B1, HSD11B2 EPHX2 670/4885F11 1094/4885KLKB1 756/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.